The Urea Cycle Disorders Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Urea Cycle Disorders Treatment Market:
According to The Business Research Company’s Urea Cycle Disorders Treatment Global Market Report 2024, The urea cycle disorders treatment market size has grown steadily in recent years. It will grow from $1.29 billion in 2023 to $1.35 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to awareness and education, improvements in newborn screening, emergence of patient support networks, standard of care guidelines.
The urea cycle disorders treatment market size is expected to see steady growth in the next few years. It will grow to $1.57 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to advancements in enzyme replacement therapy, expanded newborn screening programs, increased collaboration in research, expansion of therapeutic options, telemedicine and remote care. Major trends in the forecast period include advanced gene editing techniques, awareness and advocacy initiatives, regenerative medicine approaches, long-term safety and efficacy studies, personalized nutritional therapies:.
The rise in the prevalence of urea cycle disorders is expected to propel the growth of the urea cycle disorders treatment market going forward. Urea cycle disorder refers to metabolic disorders that are inborn and caused by flaws in one of the enzymes or transporter molecules necessary for the liver to remove ammonia from the blood. The rise in the prevalence of urea cycle disorders is driven by genetic disorders. When ammonia accumulation is identified as a urea cycle disorder (UCD), a customized treatment strategy incorporating dietary control, medication, and monitoring can be implemented to manage and lessen its negative consequences. For instance, in April 2023, according to StatPearls Publishing LLC, a US-based medical education library, the prevalence of urea cycle disorders caused by ornithine transcarbamylase deficiency was 1 in 140,000 people. Furthermore, in January 2021, according to a report shared by the National Library of Medicine, a US-based medical library run by the federal government, there were 113 new cases of urea cycle disorders for every 35,000 live births in the United States. Therefore, the rise in the prevalence of urea cycle disorders is driving the growth of the urea cycle disorders treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12237&type=smp
The urea cycle disorders treatment market covered in this report is segmented –
1) By Treatment: Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, Other Treatments
2) By Enzyme Deficiency: Ornithine Transcarbamylase (OTC), Argininosuccinate Synthetase (AS), Arginase (AG), Argininosuccinate Lyase (AL), Carbamoyl Phosphate Synthase (CPS1)
3) By Route of Administration: Oral, Injectables
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Top Major Players
F. Hoffmann-La Roche AG
AbbVie Inc.
Novartis AG
Sanofi S.A.
AstraZeneca Plc.
Product innovation has emerged as a key trend gaining popularity in the urea cycle disorder treatment market. Major companies operating in the urea cycle disorder treatment market are concentrating on creating innovative products to strengthen their position in the market. For instance, in September 2022, Medunik USA, a US-based pharmaceutical company, launched Pheburane oral pellets, a unique and flavor-masking formulation of sodium phenylbutyrate (NaPB) for the long-term management of certain urea cycle disorders. It is a prescription drug used in conjunction with a particular diet to treat urea cycle disorders (UCDs) in adults and children that involve carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinate synthetase (AS) deficiency. It is measured using a reusable, calibrated dosing spoon included in each package; unlike other forms of NaPB, it does not need to be mixed or taken orally. Pheburane can be consumed together with a snack or meal, or it can be sprinkled on a spoonful of apple sauce or carrot puree and taken with water, fruit juice, or protein-free infant formula.
The urea cycle disorders treatment market report table of contents includes:
1. Executive Summary
2. Urea Cycle Disorders Treatment Market Characteristics
3. Urea Cycle Disorders Treatment Market Trends And Strategies
4. Urea Cycle Disorders Treatment Market - Macro Economic Scenario
5. Global Urea Cycle Disorders Treatment Market Size and Growth
.........................
32. Global Urea Cycle Disorders Treatment Market Competitive Benchmarking
33. Global Urea Cycle Disorders Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Urea Cycle Disorders Treatment Market
35. Urea Cycle Disorders Treatment Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
